Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 62 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Caregivers of relatives with Alzheimer's disease are highly stressed and at risk for physical and psychiatric conditions. Interventions are usually focused on providing caregivers with knowledge of dementia, skills, and/or support, to help them cope with the stress. This model, though true to a certain extent, ignores how caregiver stress is construed in the first place. Besides burden, caregivers also report rewards, uplifts, and gains, such as a sense of purpose and personal growth. Finding benefits through positive reappraisal may offset the effect of caregiving on caregiver outcomes. Design Two randomized controlled trials are planned. They are essentially the same except that Trial 1 is a cluster trial (that is, randomization based on groups of participants) whereas in Trial 2, randomization is based on individuals. Participants are randomized into three groups - benefit finding, psychoeducation, and simplified psychoeducation. Participants in each group receive a total of approximately 12 hours of training either in group or individually at home. Booster sessions are provided at around 14 months after the initial treatment. The primary outcomes are caregiver stress (subjective burden, role overload, and cortisol), perceived benefits, subjective health, psychological well-being, and depression. The secondary outcomes are caregiver coping, and behavioral problems and functional impairment of the care-recipient. Outcome measures are obtained at baseline, post-treatment (2 months), and 6, 12, 18 and 30 months. Discussion The emphasis on benefits, rather than losses and difficulties, provides a new dimension to the way interventions for caregivers can be conceptualized and delivered. By focusing on the positive, caregivers may be empowered to sustain caregiving efforts in the long term despite the day-to-day challenges. The two parallel trials will provide an assessment of whether the effectiveness of the intervention depends on the mode of delivery. Trial registration Chinese Clinical Trial Registry (http://www.chictr.org/en/) identifier number ChiCTR-TRC-10000881.

What this study adds

Evidence grade: High

This is a trial. This is the published plan, not the results, for two randomized trials that teach family caregivers of people with Alzheimer's disease to find benefits in caregiving, such as "a sense of purpose and personal growth", as a way to ease stress. About 12 hours of benefit-finding training, given in groups or individually at home, was to be compared with psychoeducation and simplified psychoeducation.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Cheng, S. T., Lau, R. W., Mak, E. P., Ng, N. S., Lam, L. C., Fung, H. H., et al. (2012). A benefit-finding intervention for family caregivers of persons with Alzheimer disease: study protocol of a randomized controlled trial. Trials. https://doi.org/10.1186/1745-6215-13-98

Vancouver

Cheng ST, Lau RW, Mak EP, Ng NS, Lam LC, Fung HH, et al. A benefit-finding intervention for family caregivers of persons with Alzheimer disease: study protocol of a randomized controlled trial. Trials. 2012. doi:10.1186/1745-6215-13-98. PMID: 22747914.

BibTeX

@article{cheng2012-22747914,
  author  = {Cheng, S. T. and Lau, R. W. and Mak, E. P. and Ng, N. S. and Lam, L. C. and Fung, H. H. and Lai, J. C. and Kwok, T. and others},
  title   = {{A benefit-finding intervention for family caregivers of persons with Alzheimer disease: study protocol of a randomized controlled trial}},
  journal = {Trials},
  year    = {2012},
  doi     = {10.1186/1745-6215-13-98},
  pmid    = {22747914},
  url     = {https://doi.org/10.1186/1745-6215-13-98}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This is the published plan, not the results, for two randomized trials that teach family caregivers of people with Alzheimer's disease to find benefits in caregiving, such as "a sense of purpose and personal growth", as a way to ease stress. About 12 hours of benefit-finding training, given in groups or individually at home, was to be compared with psychoeducation and simplified psychoeducation. Caregiver burden, cortisol, depression, well-being and perceived benefits were to be tracked for up to 30 months. Because it contains no outcome data, it cannot show whether the approach helps caregivers; it describes a caregiver-support programme, not a treatment for Alzheimer's disease.

Study details

How this study scored 62/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 62 of 100.62 of 100 points earned38 not earned

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Trials)
Journal's citation record 1 / 4 Trials: journal h-index 132 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2012 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 4 / 7 Cited 60 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.8 citations a year over 16 year(s) since 2012
Impact for its field and year 4 / 6 Cited 10.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 8 other studies in this library
Still being cited 1 / 4 Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Diana Lee: h-index 50 (OpenAlex, whole career)
Institution's track record 1 / 3 Chinese University of Hong Kong: institution h-index 1,100 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 22747914)
Free to read 2 / 2 Free to read
Total 62 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

8 studies in the alzhub library list this one in their references.

Related studies in Treatments from nearby years

Also in Treatments

203 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →